Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FBIO

Fortress Biotech Inc

Jul 26 • 04:00PM ET

2.25

Dollar change -0.35
Percentage change -13.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC FESM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.52	Insider Own	25.59%	Shs Outstand	20.41M	Perf Week	4.65%
Market Cap	45.92M	Forward P/E	-	EPS next Y	-3.21	Insider Trans	0.68%	Shs Float	15.19M	Perf Month	32.35%
Income	-62.85M	PEG	-	EPS next Q	-1.22	Inst Own	15.68%	Short Float	9.72%	Perf Quarter	30.81%
Sales	85.11M	P/S	0.54	EPS this Y	44.39%	Inst Trans	-11.51%	Short Ratio	7.13	Perf Half Y	7.66%
Book/sh	1.19	P/B	1.89	EPS next Y	31.92%	ROA	-25.46%	Short Interest	1.48M	Perf Year	-73.14%
Cash/sh	4.21	P/C	0.53	EPS next 5Y	25.50%	ROE	-179.27%	52W Range	1.24 - 9.00	Perf YTD	-25.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.28%	ROI	-61.58%	52W High	-75.00%	Beta	1.65
Dividend TTM	-	Quick Ratio	1.21	Sales past 5Y	26.66%	Gross Margin	66.76%	52W Low	81.45%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	1.33	EPS Y/Y TTM	-37.33%	Oper. Margin	-137.40%	RSI (14)	57.02	Volatility	14.33% 8.48%
Employees	186	Debt/Eq	3.85	Sales Y/Y TTM	32.48%	Profit Margin	-73.85%	Recom	1.00	Target Price	10.75
Option/Short	Yes / Yes	LT Debt/Eq	3.43	EPS Q/Q	67.40%	Payout	-	Rel Volume	2.47	Prev Close	2.60
Sales Surprise	-7.79%	EPS Surprise	40.46%	Sales Q/Q	4.84%	Earnings	May 15 AMC	Avg Volume	207.07K	Price	2.25
SMA20	13.15%	SMA50	18.53%	SMA200	8.52%	Trades		Volume	511,583	Change	-13.46%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Jul-25-24 08:30AM	Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 (GlobeNewswire) +5.69%
07:30AM	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-15-24 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO) (Zacks)
08:00AM	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research (GlobeNewswire)
Jul-11-24 04:05PM	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors (GlobeNewswire) +12.57%
04:05PM	Loading…
Jul-05-24 04:05PM	Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (GlobeNewswire)
Jul-02-24 08:00AM	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab (GlobeNewswire)
Jun-24-24 07:30AM	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission (GlobeNewswire)
Jun-21-24 04:01PM	Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-20-24 08:30AM	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
08:00AM	Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-17-24 08:30AM	Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy (GlobeNewswire)
May-16-24 08:30AM	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
10:53PM	Loading…
May-15-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:32PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
08:30AM	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-14-24 11:14AM	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex (MT Newswires)
08:30AM	Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation (GlobeNewswire)
May-13-24 04:01PM	Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-10-24 08:30AM	Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-07-24 08:30AM	Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-02-24 04:01PM	Mustang Bio Announces Closing of $4 Million Public Offering (GlobeNewswire)
May-01-24 04:01PM	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer (GlobeNewswire)
Apr-29-24 08:00PM	Mustang Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire)
08:30AM	Loading…
Apr-25-24 08:30AM	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024 (GlobeNewswire)
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-11-24 12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Mar-28-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.83%
04:05PM	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:00AM	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire)
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-22-24 08:30AM	Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-21-24 04:01PM	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors (GlobeNewswire)
Mar-15-24 08:30AM	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 (GlobeNewswire) +15.18%
08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-13-24 08:30AM	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference (GlobeNewswire) -5.45%
Mar-12-24 08:30AM	Fortress Biotech to Participate in 36th Annual ROTH Conference (GlobeNewswire)
Mar-11-24 04:05PM	Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 07:30AM	Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma (GlobeNewswire) -6.55%
Mar-04-24 08:30AM	Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease (GlobeNewswire) -5.76%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Feb-02-24 02:40PM	Lindsay Rosenwalds Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries (News Direct) -6.09%
Jan-29-24 08:00AM	Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jan-11-24 08:30AM	Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:15AM	Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire)
08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-09-24 05:02PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ... (GuruFocus.com) -6.19% -8.49%
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire)
08:30AM	Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
Jan-03-24 04:01PM	Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -7.81%
Jan-02-24 04:05PM	Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million (GlobeNewswire) -10.63%
08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-29-23 08:20AM	Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.62%
Dec-11-23 08:30AM	Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com) +46.15%
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 11 '24	Buy	7.48	5,000	37,418	127,500	Jul 15 04:05 PM
Jin David	Chief Financial Officer	Jul 10 '24	Buy	7.50	500	3,750	500	Jul 12 08:42 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 09 '24	Buy	7.39	5,000	36,971	122,500	Jul 11 08:00 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jul 08 '24	Buy	7.35	5,000	36,764	117,500	Jul 10 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jun 28 '24	Buy	1.64	20,000	32,724	2,893,905	Jul 01 08:40 AM
Klein Dov	Director	May 20 '24	Sale	1.89	10,000	18,900	53,400	May 20 04:56 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	May 16 '24	Buy	1.76	10,000	17,589	2,873,905	May 20 05:00 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Jan 05 '24	Buy	2.38	50,000	118,770	2,863,905	Jan 09 08:15 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14 '23	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14 '23	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26 '23	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08 '23	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18 '23	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17 '23	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience